全身递送钙黏蛋白17特异性CAR T细胞可有效且安全靶向结直肠癌肝转移
研究在临床前模型中筛选钙黏蛋白17(CDH17)作为结直肠癌肝转移CAR T细胞治疗的候选抗原,设计不同抗原结合域和胞外间隔区的CDH17 CAR,比较其抗肿瘤疗效、细胞因子释放综合征和靶向/脱靶毒性。结果显示CDH17 CAR T细胞经全身或局部给药均有效抑制肿瘤生长,且对健康结肠组织无反应,支持全身递送CDH17 CAR T细胞治疗结直肠癌肝转移并推动1/2期临床试验。
要点
- CDH17 CAR T细胞经全身或局部给药均有效抑制结直肠癌肝转移模型肿瘤生长。
- CDH17在肿瘤细胞整个表面暴露,在健康结肠仅局限于上皮细胞侧连接处。
- 局部注射CDH17 CAR T细胞在重建人免疫系统小鼠中引起特别严重的细胞因子释放综合征。
核心结论
- 这些发现支持全身递送CDH17 CAR T细胞作为治疗结直肠癌肝转移的安全有效方法,并为1/2期临床试验铺平道路。
研究设计与样本
- 研究在临床前模型中设计并比较了不同抗原结合域和胞外间隔区的人CDH17 CAR,评估抗肿瘤疗效、细胞因子释放综合征和靶向/脱靶毒性。
- 使用结直肠癌肝转移异种移植模型和重建人免疫系统的小鼠进行测试。
主要发现
- 不同结合域在体外疗效不同,而间隔区影响CAR T细胞体内动力学。
- 在结直肠癌肝移植模型中,CDH17 CAR T细胞经全身或局部给药均有效抑制肿瘤生长。
- 在重建人免疫系统的小鼠中,局部注射的CAR T细胞引起特别严重的细胞因子释放综合征。
- 共聚焦显微镜显示CDH17暴露于肿瘤细胞整个表面,而在健康结肠中其表达局限于上皮细胞侧连接处。
- CDH17 CAR T细胞对结直肠癌组织切片显示剂量依赖性细胞因子释放,而对健康结肠组织样本无反应。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Liver metastases represent the leading cause of death in patients with colorectal cancer (CRC). Chimeric antigen receptor (CAR) T cell therapy holds promise in this context, but any effort to bring it to the bedside requires careful antigen selection and testing in clinically relevant models. Here, we identified cadherin-17 (CDH17) as a candidate antigen for CAR T cell therapy of CRC liver metastases. We hence designed human CDH17 CARs differing in antigen binding and extracellular spacer regions and compared the different constructs in preclinical models of antitumor efficacy, cytokine release syndrome, and on-target off-tumor toxicity. Whereas the binding domains differed in efficacy in vitro, the spacer region shaped the kinetics of the CAR T cells in vivo. When used in a CRC liver xenograft model, CDH17 CAR T cells efficiently suppressed tumor growth upon either systemic or locoregional administration. However, when tested in mice reconstituted with a human immune system, CAR T cells injected locally caused a particularly harsh cytokine release syndrome. Confocal microscopy revealed that CDH17 is exposed on the entire surface of tumor cells, whereas its expression in healthy colon is restricted to lateral junctions between epithelial cells. Accordingly, CDH17 CAR T cells showed dose-dependent cytokine release in response to CRC tissue slices while displaying no reaction against healthy colon tissue samples. Overall, these findings support systemic delivery of CDH17 CAR T cells as a safe and effective approach to treat CRC liver metastases and pave the way for a phase 1/2 clinical trial.
引用
- Greco B, El Khoury R, Balestrieri C, et al. Systemic delivery of cadherin 17-specific CAR T cells allows effective and safe targeting of colorectal cancer liver metastases. Sci Transl Med. 2025. PMID: 40435215. doi:10.1126/scitranslmed.adr1928
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。